Integrative Medicine Rehabilitation for Children with Cerebral Palsy: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CRIS

Registry ID

KCT0002620

Enrollment

Registered

2017-12-29

Start date

2018-03-01

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug, Procedure/Surgery : Yukkunzatang Ex. and Yukmijihwangtang Ex.( Kracie pharma korea co. ) are taken orally for 12 weeks. Daily dose of medicine is 4-6g(Yukkunzatang Ex.: 2-3g, Yukmijihwangtang Ex

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Children of 1 to 6 years of age diagnosed with cerebral palsy (For premature babies, the age is calculated using the corrective age for up to 24 months.) 2.Pediatric patients whose parents have agreed to participate in the study

Exclusion criteria

Exclusion criteria: 1.Children who have orthopedic surgery within 6 months before recruitment 2.Children with botox treatment within 6 months before recruitment 3.Children with Degenerative brain disease, Congenital neuromuscular disease, uncontrolled seizures 4.Children who participated in other clinical trials within 3 months prior to recruitment or children participating in other clinical studies now. 5.Children who are treated with other serious diseases (such as tumors, heart disease, severe infectious diseases, etc.) other than cerebral palsy 6. Children who are judged by other researchers to be difficult to participate in clinical research. 7. Children who have pediatric problems with lactose, galactose degradation, absorption 8. Children with hypersensitivity to ginseng, Atractylodes macrocephala Koidzumi,Poria cocos Wolf, Pinellia ternata, Fraxinus rhynchophylla, Zizyphus jujuba, Glycyrrhizae Radix, Zingiberis Rhizoma Recens. 9. Children with hypersensitivity to Rehmanniae Radix, Corni Fructus, Dioscoreae Rhizoma, Alismatis Rhizoma, Moutan Cortex. 10. Children who have liver or kidney hypofunction. 11. Children who are sensitive to medicines

Design outcomes

Primary

Measure	Time frame
Gross Motor function Measure-88	—

Secondary

Measure	Time frame
Goal Attainment Scaling;Korean Bayley Scales of Infant Development (K-BSID-3);Pediatric Quality of Life Inventory	—

Countries

Korea, Republic of

Contacts

Public ContactMijoo Lee

Bundang CHA General Hospital

jandi916@naver.com+82-31-780-6114

Outcome results